STTK

Shattuck Labs, Inc. (STTK) | Rumor.io

Shattuck Labs

STTK

Attention (50-day avg)0%

Attention rank (50-day avg)#2,864

Bullish sentiment (50-day avg)75%

Price to earnings ratio-9.22

Market capitalization645.3M

Earnings per share-0.44

Dividend yield (TTM)—

Revenue (annual)1M

Net income (annual)-48.8M

Social

What share of all stock conversation is about STTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 8

Shattuck Labs, Inc. ($STTK) announced positive Phase 1 results for its DR3 blocking antibody SL-325, with complete receptor occupancy occurring at ≥0.1 mg/kg and TL1A blockade lasting over 10 days.
Citigroup raised its target price for $STTK to $18.00 from $7.00 following the positive trial results.
$STTK stock price increased by 16.6% pre-market after the announcement, with some investors expressing confusion over the stock's decline to $4.08 following the news.

Generated by AI

Sentiment

Of the messages about STTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -40	91.3% +8.48
Bearish	—	—	40% new	8.7% -8.48

Bullish· Jun 5

Citi upgrades Shattuck Labs, Inc. (STTK) to Buy with a $7 price target.
Shattuck Labs' SL-325 Phase 1 data in Q2 2026 is a key catalyst for the stock's upside.
The upgrade and price target increase reflect Citi's positive outlook on the company's prospects.

Bearish· Aug 5

The company may be diluting shares with a large influx of new stock, potentially capping the stock's price unless a strong catalyst emerges.
The stock has a two-star rating, indicating a low level of investor confidence.
A significant amount of dilution is expected if the company receives IND clearance for its SL-325 trial, which could lead to a drop in the stock's price.

Generated by AI

Topics

Of the messages about STTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	59.48%
Technical Analysis	—	—	100%	25.86%
Earnings	—	—	0%	0.86%
Analysts	—	—	0%	3.88%
Controversies	—	—	0%	0%
Macro	—	—	0%	9.91%

Announcements· Aug 5

Shattuck Labs, Inc. (STTK) announced an oversubscribed private placement of up to $103 million, led by OrbiMed with participation from healthcare-dedicated funds and existing investors.
The company plans to use the net proceeds to fund the clinical development of its lead candidate SL-325, including multiple Phase 2 clinical trials in IBD and another autoimmune disease, and for general corporate purposes.
The private placement is expected to fund operations into 2029, with the company securing development funding for multiple Phase 2 clinical trials and extending its cash runway into 2029.

Controversies· Feb 15

Shattuck Labs, Inc. (STTK) is facing a class action lawsuit with a looming deadline, according to a law firm's notice.
Investors are reminded to take action in the lawsuit against Shattuck Labs, Inc. (STTK) with a deadline set for a specific date.
A law firm has announced a lead plaintiff deadline for the class action lawsuit against Shattuck Labs, Inc. (STTK) regarding securities claims.

Technical Analysis· Aug 5

$STTK has a key level of $0.96 that holds, potentially leading to a move up to $1.20 and $1.40.
A chart pattern known as the "trident" has been observed on $STTK, which may signify a good chance for a solid move up on open.
$STTK has broken past resistance lines, with RSI surging into bullish territory, and is currently holding above $0.99 support with stacked EMAs.

Generated by AI

Community

Of the messages about STTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	87.5%	18.44%
Newcomers	0%	0%	12.5%	81.56%

Regulars· Feb 13

The regulars are excited about the potential targets for Shattuck Labs' agonists, with one user speculating that CD19/CD3 + cytokine agonist might be a possibility.
Shattuck Labs has entered into a strategic collaboration and license agreement with Ono Pharmaceutical to generate bifunctional fusion proteins for the treatment of autoimmune and inflammatory diseases.
The partnership between Shattuck Labs and Ono Pharmaceutical is seen as a positive development, with the stock price of Shattuck Labs experiencing a significant increase in the pre-market.

Newcomers· Jun 8

The stock price of Shattuck Labs, Inc. ($STTK) dipped approximately 10.9% to $4.08 due to clinical trial delays, causing short-term uncertainty and institutional outflows.
Some investors, such as Abrdn Life Sciences fundholders, took gains in $STTK this spring, implying a positive view of the company's prospects.
Shattuck Labs reported positive Phase 1 trial results for SL-325, a treatment for immune-related disease, with good safety results and a subsequent 17% increase in stock price.

Generated by AI

News

Shattuck Labs Stock: A Receptor-Side Bet On The TL1A Boom (NASDAQ:STTK)

Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing oncology. Read why STTK stock is a buy.

29d agoSeeking Alpha

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

29d agoSeeking Alpha

What Shattuck Labs Stock Topped the Market on Monday

Two analysts weighed in with new takes on the biotech.

1mo agoYahoo Finance

Raymond James initiates Shattuck Labs stock with strong buy rating

1mo agoInvesting.com

Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target

Shattuck Labs (STTK) has an average rating of buy and mean price target of $15, according to analyst

1mo agoYahoo Finance

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

1mo agoYahoo Finance

Also Discussed

Investors talking about STTK also mention

#	Name	Attention
1	C4 Therapeutics IncCCCC	0%new
2	ALX Oncology Holdings Inc.ALXO	0%0
3	Sera Prognostics, Inc. Class A Common StockSERA	0%0
4	I-Mab Sponsored ADRIMAB	0%0
5	IN8bio, Inc.INAB	0%0
6	Arcutis Biotherapeutics, Inc.ARQT	0%+0
7	Naya Biosciences Inc.INVO	0%0
8	Q32 Bio Inc.QTTB	0%+0
9	Relmada Therapeutics Inc.RLMD	0%0
10	THTX - Theratechnologies Inc.	——

Shattuck Labs, Inc.

Healthcare
Biotechnology

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases. The company’s lead program centers on SL-325, a DR3 antagonist antibody designed to target the TL1A/DR3 pathway, which is being studied for inflammatory bowel disease and related conditions. Shattuck Labs is also advancing SL-425, a half-life extended version of SL-325, along with additional preclinical DR3-based antibody candidates. Its research is built around protein engineering and novel therapeutic designs intended to modulate immune signaling more precisely. Based in Austin, Texas, Shattuck Labs operates within the broader biopharmaceutical market, where its current pipeline is aimed at addressing immune-driven diseases with significant unmet medical need.

Website

Location

500 West 5th Street

Austin, TX, 78701

United States

Social

What share of all stock conversation is about STTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 8

Shattuck Labs, Inc. ($STTK) announced positive Phase 1 results for its DR3 blocking antibody SL-325, with complete receptor occupancy occurring at ≥0.1 mg/kg and TL1A blockade lasting over 10 days.
Citigroup raised its target price for $STTK to $18.00 from $7.00 following the positive trial results.
$STTK stock price increased by 16.6% pre-market after the announcement, with some investors expressing confusion over the stock's decline to $4.08 following the news.

Generated by AI

Sentiment

Of the messages about STTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -40	91.3% +8.48
Bearish	—	—	40% new	8.7% -8.48

Bullish· Jun 5

Citi upgrades Shattuck Labs, Inc. (STTK) to Buy with a $7 price target.
Shattuck Labs' SL-325 Phase 1 data in Q2 2026 is a key catalyst for the stock's upside.
The upgrade and price target increase reflect Citi's positive outlook on the company's prospects.

Bearish· Aug 5

The company may be diluting shares with a large influx of new stock, potentially capping the stock's price unless a strong catalyst emerges.
The stock has a two-star rating, indicating a low level of investor confidence.
A significant amount of dilution is expected if the company receives IND clearance for its SL-325 trial, which could lead to a drop in the stock's price.

Generated by AI

Topics

Of the messages about STTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	59.48%
Technical Analysis	—	—	100%	25.86%
Earnings	—	—	0%	0.86%
Analysts	—	—	0%	3.88%
Controversies	—	—	0%	0%
Macro	—	—	0%	9.91%

Announcements· Aug 5

Shattuck Labs, Inc. (STTK) announced an oversubscribed private placement of up to $103 million, led by OrbiMed with participation from healthcare-dedicated funds and existing investors.
The company plans to use the net proceeds to fund the clinical development of its lead candidate SL-325, including multiple Phase 2 clinical trials in IBD and another autoimmune disease, and for general corporate purposes.
The private placement is expected to fund operations into 2029, with the company securing development funding for multiple Phase 2 clinical trials and extending its cash runway into 2029.

Controversies· Feb 15

Shattuck Labs, Inc. (STTK) is facing a class action lawsuit with a looming deadline, according to a law firm's notice.
Investors are reminded to take action in the lawsuit against Shattuck Labs, Inc. (STTK) with a deadline set for a specific date.
A law firm has announced a lead plaintiff deadline for the class action lawsuit against Shattuck Labs, Inc. (STTK) regarding securities claims.

Technical Analysis· Aug 5

$STTK has a key level of $0.96 that holds, potentially leading to a move up to $1.20 and $1.40.
A chart pattern known as the "trident" has been observed on $STTK, which may signify a good chance for a solid move up on open.
$STTK has broken past resistance lines, with RSI surging into bullish territory, and is currently holding above $0.99 support with stacked EMAs.

Generated by AI

Community

Of the messages about STTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	87.5%	18.44%
Newcomers	0%	0%	12.5%	81.56%

Regulars· Feb 13

The regulars are excited about the potential targets for Shattuck Labs' agonists, with one user speculating that CD19/CD3 + cytokine agonist might be a possibility.
Shattuck Labs has entered into a strategic collaboration and license agreement with Ono Pharmaceutical to generate bifunctional fusion proteins for the treatment of autoimmune and inflammatory diseases.
The partnership between Shattuck Labs and Ono Pharmaceutical is seen as a positive development, with the stock price of Shattuck Labs experiencing a significant increase in the pre-market.

Newcomers· Jun 8

The stock price of Shattuck Labs, Inc. ($STTK) dipped approximately 10.9% to $4.08 due to clinical trial delays, causing short-term uncertainty and institutional outflows.
Some investors, such as Abrdn Life Sciences fundholders, took gains in $STTK this spring, implying a positive view of the company's prospects.
Shattuck Labs reported positive Phase 1 trial results for SL-325, a treatment for immune-related disease, with good safety results and a subsequent 17% increase in stock price.

Generated by AI

Shattuck Labs

Social

Jun 8

Bullish· Jun 5

Bearish· Aug 5

Announcements· Aug 5

Controversies· Feb 15

Technical Analysis· Aug 5

Regulars· Feb 13

Newcomers· Jun 8

Shattuck Labs Stock: A Receptor-Side Bet On The TL1A Boom (NASDAQ:STTK)

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

What Shattuck Labs Stock Topped the Market on Monday

Raymond James initiates Shattuck Labs stock with strong buy rating

Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

Also Discussed

Shattuck Labs, Inc.

Company Information

Location

Shattuck Labs Stock: A Receptor-Side Bet On The TL1A Boom (NASDAQ:STTK)

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

What Shattuck Labs Stock Topped the Market on Monday

Raymond James initiates Shattuck Labs stock with strong buy rating

Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

Also Discussed

Social

Jun 8

Bullish· Jun 5

Bearish· Aug 5

Announcements· Aug 5

Controversies· Feb 15

Technical Analysis· Aug 5

Regulars· Feb 13

Newcomers· Jun 8